Journal List > J Korean Acad Periodontol > v.39(1) > 1049827

Kwon, Lim, Choi, Kim, Lee, Jung, Yun, Kim, Choi, and Cho: Effect of rhBMP-2 produced by Escherichia coli expression system on bone formation in rat calvarial defects

Abstract

Purpose

Recombinant human bone morphogenetic protein-2(rhBMP-2) has been evaluated as potential candidates for periodontal and bone regenerative therapy. In spite of good prospects in BMP applications, there is economically unavailable for clinical use in dental area. The purpose of this study was to evaluate the osteogenic effect of rhBMP-2 produced by E.coli expression system.

Materials and methods

Eight-mm critical-size calvarial defects were created in 48 male Sprague-Dawley rats. The animals were divided into 6 groups of 8 animals each. Each group received one of the following: Negative control(sham-surgery control), positive control(absorbable collagen sponge(ACS) alone) and experimental(ACS loaded with rhBMP-2). Defects were evaluated by histologic and histometric parameters following 2- and 8-week healing intervals.

Results

The experimental group showed significant defect closure at 2 and 8weeks than the sham surgery and positive control groups. Moreover, the experimental group showed significantly greater new bone and augmented area than the other groups at both 2 and 8weeks.

Conclusion

rhBMP-2 produced by E.coli expression system may be effective for bone regeneration.

Figures and Tables

Figure 1
Schematic diagram of the calvarial osteotomy defect showing the histometric analysis
jkape-39-77-g001
Figure 2
Representative photomicrographs of defect site receiving the sham surgery at 2weeks(arrow heads : defect margin ; HE stain, magnification × 10).
jkape-39-77-g002
Figure 3
Representative photomicrographs of defect site receiving the sham surgery at 8weeks(arrow heads : defect margin ; HE stain, magnification × 10).
jkape-39-77-g003
Figure 4
Representative photomicrographs of defect site receiving the positive control at 2weeks(arrow heads : defect margin ; HE stain, magnification × 10).
jkape-39-77-g004
Figure 5
Representative photomicrographs of defect site receiving the positive control at 8weeks(arrow heads : defect margin ; HE stain, magnification × 10).
jkape-39-77-g005
Figure 6
Representative photomicrographs of defect site receiving the experimental at 2weeks(arrow heads:defect margin ; HE stain, magnification × 10).
jkape-39-77-g006
Figure 7
Representative photomicrographs of defect site receiving the experimental at 2weeks(arrow heads:defect margin, PB:pre-existing bone, NB:new bone ; HE stain, magnification × 100).
jkape-39-77-g007
Figure 8
Representative photomicrographs of defect site receiving the experimental at 2weeks(central portion ; HE stain, magnification × 100)
jkape-39-77-g008
Figure 9
Representative photomicrographs of defect site receiving the experimental at 8weeks(arrow heads: defect margin ; HE stain, magnification × 10).
jkape-39-77-g009
Figure 10
Representative photomicrographs of defect site receiving the experimental at 8weeks(arrow heads:defect margin, PB:pre-existing bone, NB:new bone ; HE stain, magnification × 100).
jkape-39-77-g010
Figure 11
Representative photomicrographs of defect site receiving the experimental at 8weeks(central portin; HE stain, magnification × 100).
jkape-39-77-g011
Table 1
Study design
jkape-39-77-i001
Table 2
Defect closure(group means±SD; n=8, %)
jkape-39-77-i002

*: Statistically significant difference compared with the negative control group (P<0.05)

: Statistically significant difference compared with the positive control group (P<0.05)

: Statistically significant difference compared with that observed at 2 weeks (P<0.05)

Table 3
New bone area(group means±SD; n=8, mm2)
jkape-39-77-i003

*: Statistically significant difference compared with the negative control group (P<0.05)

: Statistically significant difference compared with the positive control group (P<0.05)

: Statistically significant difference compared with that observed at 2 weeks (P<0.05)

Table 4
Augmented area(group means±SD; n=8, mm2)
jkape-39-77-i004

*: Statistically significant difference compared with the negative control group (P<0.05)

: Statistically significant difference compared with the positive control group (P<0.05)

: Statistically significant difference compared with that observed at 2 weeks (P<0.05)

References

1. Urist MR. Bone: formation by autoinduction. Science. 1965. 150:893–899.
crossref
2. Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res. 1971. 50:1392–1406.
crossref
3. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988. 242:1528–1534.
crossref
4. Reddi AH, Anderson WA. Collagenous bone matrix-induced endochondral ossification hemopoiesis. J Cell Biol. 1976. 69:557–572.
crossref
5. Thies RS, Bauduy M, Ashton BA, et al. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology. 1992. 130:1318–1324.
crossref
6. Hiraki Y, Inoue H, Shigeno C, et al. Bone morphogenetic proteins (BMP-2 and BMP-3) promote growth and expression of the differentiated phenotype of rabbit chondrocytes and osteoblastic MC3T3-E1 cells in vitro. J Bone Miner Res. 1991. 6:1373–1385.
crossref
7. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994. 127:1755–1766.
crossref
8. Knutsen R, Wergedal JE, Sampath TK, et al. Osteogenic protein-1 stimulates proliferation and differentiation of human bone cells in vitro. Biochem Biophys Res Commun. 1993. 194:1352–1358.
crossref
9. Kobayashi M, Takiguchi T, Suzuki R, et al. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic differentiation in cells isolated from human periodontal ligament. J Dent Res. 1999. 78:1624–1633.
crossref
10. Takuwa Y, Ohse C, Wang EA, et al. Bone morphogenetic protein-2 stimulates alkaline phosphatase activity and collagen synthesis in cultured osteoblastic cells, MC3T3-E1. Biochem Biophys Res Commun. 1991. 174:96–101.
crossref
11. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 1993. 9:57–71.
crossref
12. Yamaguchi A, Ishizuya T, Kintou N, et al. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem Biophys Res Commun. 1996. 220:366–371.
crossref
13. Sampath TK, Maliakal JC, Hauschka PV, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem. 1992. 267:20352–20362.
crossref
14. Aldinger G, Herr G, Kusswetter W, et al. Bone morphogenetic protein: a review. Int Orthop. 1991. 15:169–177.
crossref
15. Alam I, Asahina I, Ohmamiuda K, Enomoto S. Comparative study of biphasic calcium phosphate ceramics impregnated with rhBMP-2 as bone substitutes. J Biomed Mater Res. 2001. 54:129–138.
crossref
16. Gao TJ, Lindholm TS, Kommonen B, et al. Enhanced healing of segmental tibial defects in sheep by a composite bone substitute composed of tricalcium phosphate cylinder, bone morphogenetic protein, and type IV collagen. J Biomed Mater Res. 1996. 32:505–512.
crossref
17. King GN, King N, Hughes FJ. Effect of two delivery systems for recombinant human bone morphogenetic protein-2 on periodontal regeneration in vivo. J Periodontal Res. 1998. 33:226–236.
crossref
18. Sampath TK, Reddi AH. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc Natl Acad Sci U S A. 1981. 78:7599–7603.
crossref
19. Urist MR, Lietze A, Dawson E. Beta-tricalcium phosphate delivery system for bone morphogenetic protein. Clin Orthop Relat Res. 1984. 277–280.
20. Urist MR, Nilsson O, Rasmussen J, et al. Bone regeneration under the influence of a bone morphogenetic protein(BMP) beta tricalcium phosphate(TCP) composite in skull trephine defects in dogs. Clin Orthop Relat Res. 1987. 295–304.
21. Jovanovic SA, Hunt DR, Bernard GW, et al. Bone reconstruction following implantation of rhBMP-2 and guided bone regeneration in canine alveolar ridge defects. Clin Oral Implants Res. 2007. 18:224–230.
crossref
22. Sigurdsson TJ, Fu E, Tatakis DN, et al. Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration. Clin Oral Implants Res. 1997. 8:367–374.
crossref
23. Han DK, Kim CS, Jung UW, et al. Effect of a fibrin-fibronectin sealing system as a carrier for recombinant human bone morphogenetic protein-4 on bone formation in rat calvarial defects. J Periodontol. 2005. 76:2216–2222.
crossref
24. Hong SJ, Kim CS, Han DK, et al. The effect of a fibrin-fibronectin/beta-tricalcium phosphate/recombinant human bone morphogenetic protein-2 system on bone formation in rat calvarial defects. Biomaterials. 2006. 27:3810–3816.
crossref
25. Wang EA, Rosen V, D'Alessandro JS, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A. 1990. 87:2220–2224.
crossref
26. Choi KH, Moon KO, Kim SH, et al. Purification and biological activity of recombinant human bone morphogenetic protein-2 produced by E.coli expression system. J Korean Acad Periodontol. 2008. 38:41–50.
crossref
27. Vallejo LF, Brokelmann M, Marten S, et al. Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. J Biotechnol. 2002. 94:185–194.
crossref
28. Katagiri T, Yamaguchi A, Ikeda T, et al. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun. 1990. 172:295–299.
crossref
29. Takagi K, Urist MR. The reaction of the dura to bone morphogenetic protein (BMP) in repair of skull defects. Ann Surg. 1982. 196:100–109.
crossref
30. Lynch SE, Marx RE, Nevins M, Wisner-Lynch LA. Tissue Engineering - Application in oral and maxillofacial surgery and periodontics. 2008. 2nd Edition. Chicago: Quintessence Publishing Co, Inc;163–165.
31. Ahn SH, Kim CS, Suk HJ, et al. Effect of recombinant human bone morphogenetic protein-4 with carriers in rat calvarial defects. J Periodontol. 2003. 74:787–797.
crossref
32. Pang EK, Im SU, Kim CS, et al. Effect of recombinant human bone morphogenetic protein-4 dose on bone formation in a rat calvarial defect model. J Periodontol. 2004. 75:1364–1370.
crossref
33. Martin GJ Jr, Boden SD, Marone MA, et al. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate : Important lessons learned regarding dose, carrier, and safety. J Spinal Disord. 1999. 12:179–186.
34. Hsu HP, Zanella JM, Peckham SM, et al. Comparing Ectopic Bone Growth Induced by rhBMP-2 on an Absorbable Collagen Sponge in Rat and Rabbit Models. J Orthop Res. 2006. 24:1660–1669.
crossref
35. Yang X, Fang J, Luo Y. Effects of recombinant human bone morphogenetic protein 2 and osteogenic agents on proliferation and differentiation of rat mesenchymal stem cells. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007. 21:140–144.
TOOLS
Similar articles